drugset / Trial / NCT02836652

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

NCT02836652

Phase 4 Completed 72 enrolled Abbott Medical Devices
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is a prospective, multi-center, randomized, double-blind placebo-controlled study of subjects receiving the HM II LVAD as per the current FDA approved indications for use.

Timeline

Start
2016-11
Primary completion
2019-02-21
Completion
2019-07-18

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 81 mg
Background Warfarin Small molecule

Indications